Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Letetresgene autoleucel + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Adaptimmune Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Letetresgene autoleucel (lete-cel; GSK3377794) is a genetically modified autologous T-cell therapy engineered to express an enhanced T-cell receptor (TCR) specific for the cancer-testis antigens NY-ESO-1 and LAGE-1a. It is designed to target and eliminate tumor cells expressing these antigens in patients who are HLA-A*02:01, *02:05, or *02:06 positive. Pembrolizumab (Keytruda) is a monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1), thereby enhancing immune responses against tumors. The combination of letetresgene autoleucel with pembrolizumab has been investigated in clinical trials for relapsed/refractory multiple myeloma and advanced non-small cell lung cancer, as well as other solid tumors such as myxoid/round cell liposarcoma. Letetresgene autoleucel has demonstrated manageable safety and transient antitumor activity, while pembrolizumab provides additional immune checkpoint inhibition[1][5][6][8].
- Other names
- pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)L Antigen Family Member 1a peptide/Human Leukocyte Antigen-A*02:01/02:05/02:06 complexNew York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide/HLA-A*02:01/02:05/02:06 complex
Beyond the preview
Go deeper on Letetresgene autoleucel + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Letetresgene autoleucel + pembrolizumab.